Shannon Campbell
Known title: DirectorCIK: 0002018966
Associated companies
Transaction History
| ZNTL | ▲ Buy | Grant | 114,200 | $0 | 5/26/2026 | View on chart |
| BDTX | ▲ Buy | Grant | 4,500 | $11K | 12/13/2024 | View on chart |
| BDTX | ▲ Buy | Grant | 2,354 | $11K | 9/20/2024 | View on chart |
| BDTX | ▲ Buy | Grant | 2,011 | $10K | 6/21/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Leerink Partners initiates coverage of Zentalis at Outperform
Leerink Partners has begun covering Zentalis Pharmaceuticals with an Outperform rating and a price target of $8. This new analyst note places the target above the current average analyst estimate of $6.89. The move adds to the recent analyst activity surrounding the stock, which is currently trading near its 52-week range midpoint.
Leerink Partners initiates coverage of Zentalis at Outperform. Leerink Partners has begun covering Zentalis Pharmaceuticals with an Outperform rating and a price target of $8. This new analyst note places the target above the current average analyst estimate of $6.89. The move adds to the recent analyst activity surrounding the stock, which is currently trading near its 52-week range midpoint.